基于网络药理学研究参附注射液治疗脓毒症的作用机制

doi:10.3976/j.issn.1002-4026.2022.01.004

摘要/Abstract

摘要：

利用网络药理学和分子对接方法研究参附注射液治疗脓毒症的物质基础及其可能的作用机制。通过中药系统药理学数据库与分析平台和SwissTargetPrediction数据库得到参附注射液活性成分及其药物靶点,通过 GeneCards、OMIM和Drugbank数据库筛选得到脓毒症相关靶点,STRING数据库和Cytoscape软件构建蛋白质-蛋白质相互作用网络;使用Metascape平台进行基因本体(gene ontology,GO)和基于京都基因与基因组百科全书(Kyoto encyclopedia of genes and genomes,KEGG)通路分析;应用Cytoscape软件构建成分-靶点-通路网络;应用AutoDock软件对关键成分和靶点进行分子对接;尾静脉注射LPS建立小鼠脓毒症模型,利用ELISA 和Western blot验证参附注射液对脓毒症的治疗效果。结果表明:参附注射液的潜在活性成分共有34个,其治疗脓毒症的关键靶点137个,GO和KEGG分析靶点主要涉及炎症、细胞凋亡和信号转导等生物学过程,通过PI3K-Akt和MAPK等信号通路治疗脓毒症;分子对接结果显示关键成分与对应靶点具有较好的结合活性;体内实验验证结果表明,参附注射液能够抑制脓毒症小鼠血清中的炎症因子TNF-α和IL-6表达;Western blot结果表明,参附注射液可以上调肝组织中ERK表达(P<0.01),下调p-ERK的表达(P<0.01)。该研究发现参附注射液是通过多成分-多靶点-多通路的作用方式发挥抗脓毒症作用,为明确其抗脓毒症的作用机制提供了科学依据。

关键词: 参附注射液, 脓毒症, 网络药理学, 分子对接, 体内实验

Abstract:

This study aimed to study the material basis of Shenfu Injection in the treatment of sepsis and its possible mechanism of action using network pharmacology and molecular docking methods. Traditional Chinese Medicine System Pharmacology Database and Analysis Platform and Swiss Target Prediction database were used to identify the potential active ingredients and drug targets of Shenfu Injection. Screening of disease targets was performed using GeneCards, OMIM, and Drugbank databases. String database and Cytoscape software were used to construct a protein-protein interaction network. Metascape platform was used for gene ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses. Cytoscape software was used to construct a component-target-pathway network. Auto Dock software was used to perform molecular docking of the key components and targets. A mouse sepsis model was developed by injecting LPS into the tail vein. The therapeutic effect of Shenfu Injection on sepsis was verified using ELISA and western blot. The results revealed 34 potential active ingredients in Shenfu Injection and 137 key targets involved in sepsis treatment. The results of GO and KEGG analyses showed that these targets primarily involved biological processes such as inflammation, apoptosis, and signal transduction and played a role in sepsis treatment through signaling pathways such as PI3K-Akt and MAPK. The results of molecular docking revealed that the key components had good binding activities with the corresponding targets. In vivo experiments verified that Shenfu Injection inhibits the expression of inflammatory factors TNF-α and IL-6 in septic mice. Western blot results showed that Shenfu Injection could significantly upregulate ERK expression (P<0.01) and downregulate p-ERK expression (P<0.01) in liver tissues. This study found that Shenfu Injection exerts its antiseptic effect through a multicomponent-multitarget-multipathway mode of action, which provides an important scientific basis for clarifying its antisepsis mechanism.

Key words: Shenfu Injection, sepsis, network pharmacology, molecular docking, in vivo experiment

中图分类号:

R285

应天昊,余涛,赵佳宁,孙萌萌,祝璇,李晓丽,唐一迪,张雷明. 基于网络药理学研究参附注射液治疗脓毒症的作用机制[J]. 山东科学, 2022, 35(1): 18-27.

YING Tian-hao,YU Tao,ZHAO Jia-ning,SUN Meng-meng,ZHU Xuan,LI Xiao-li,TANG Yi-di,ZHANG Lei-ming. Mechanism of Shenfu Injection in the treatment of sepsis based on network pharmacology[J]. Shandong Science, 2022, 35(1): 18-27.

图/表 8

图1

图2

图3

图4

图5

图6

图7

图8

参考文献 33

[1]	HUANG M, CAI S L, SU J Q. The pathogenesis of sepsis and potential therapeutic targets[J]. International Journal of Molecular Sciences, 2019, 20(21):5376. DOI: 10.3390/ijms20215376. doi: 10.3390/ijms20215376
[2]	REINHART K, DANIELS R, KISSOON N, et al. Recognizing sepsis as a global health priority:A WHO resolution[J]. The New England Journal of Medicine, 2017, 377(5):414-417.DOI: 10.1056/NEJMp1707170. doi: 10.1056/NEJMp1707170
[3]	FLEISCHMANN C, SCHERAG A, ADHIKARI N K J, et al. Assessment of global incidence and mortality of hospital-treated sepsis. current estimates and limitations[J]. American Journal of Respiratory and Critical Care Medicine, 2016, 193(3):259-272. DOI: 10.1164/rccm.201504-0781OC. doi: 10.1164/rccm.201504-0781OC
[4]	何健卓, 黄宇新, 蔡彦, 等. “扶正祛邪、截断扭转”论治新型冠状病毒肺炎并发脓毒症的机制与实践[J]. 中国中西医结合杂志, 2020, 40(7):858-862. DOI: 10.7661/j.cjim.20200609.236. doi: 10.7661/j.cjim.20200609.236
[5]	赖江龙, 王雁, 陈吉婷. 益气扶正、化瘀解毒法治疗脓毒症合并凝血功能障碍临床研究[J]. 亚太传统医药, 2017, 13(20):121-122. DOI: 10.11954/ytctyy.201720047. doi: 10.11954/ytctyy.201720047
[6]	胡斌, 刘冰, 赵浩延, 等. 中医药治疗脓毒症的研究进展[J]. 中国医药指南, 2020, 18(22):32-33. DOI: 10.15912/j.cnki.gocm.2020.22.012. doi: 10.15912/j.cnki.gocm.2020.22.012
[7]	曾德金. 参附注射液的药理研究及临床应用进展[J]. 中西医结合研究, 2019, 11(3):159-161. DOI: 10.3969/j.issn.1674-4616.2019.03.017. doi: 10.3969/j.issn.1674-4616.2019.03.017
[8]	贾波, 李冀. 方剂学[M].9版. 北京: 中国中医药出版社, 2018:43-44.
[9]	曹钰, 柴艳芬, 邓颖, 等. 中国脓毒症/脓毒性休克急诊治疗指南(2018)[J]. 临床急诊杂志, 2018, 19(9):567-588. DOI: 10.13201/j.issn.1009-5918.2018.09.001. doi: 10.13201/j.issn.1009-5918.2018.09.001
[10]	潘阳, 陈晓庆. 脓毒症休克治疗中参附注射液的应用价值[J]. 中外医学研究, 2020, 18(27):47-48. DOI: 10.14033/j.cnki.cfmr.2020.27.019. doi: 10.14033/j.cnki.cfmr.2020.27.019
[11]	尹明新, 张维杰, 陈璐, 等. 参附注射液对脓毒症休克患者早期液体复苏临床疗效的Meta分析[J]. 中国中医急症, 2020, 29(10):1754-1758. DOI: 10.3969/j.issn.1004-745X.2020.10.016. doi: 10.3969/j.issn.1004-745X.2020.10.016
[12]	赵男, 张达. 参附注射液在改善脓毒症休克治疗的价值[J]. 海峡药学, 2020, 32(8):117-119.
[13]	SHI X Q, YUE S J, TANG Y P, et al. A network pharmacology approach to investigate the blood enriching mechanism of Danggui buxue Decoction[J]. Journal of Ethnopharmacology, 2019, 235:227-242. DOI: 10.1016/j.jep.2019.01.027. doi: 10.1016/j.jep.2019.01.027
[14]	赵国桢, 郭玉红, 李博, 等. 中医药防治脓毒症的研究进展[J]. 中国中药杂志, 2017, 42(8):1423-1429. DOI: 10.19540/j.cnki.cjcmm.2017.0038. doi: 10.19540/j.cnki.cjcmm.2017.0038
[15]	柴瑞平, 路娟, 赵颖, 等. 中药注射液防治脓毒症的研究进展[J]. 中华中医药杂志, 2019, 34(6):2617-2619.
[16]	谢秀芳, 李多, 熊彬, 等. 外源性ghrelin在脓毒症小鼠肺脏炎症反应中的作用[J]. 中国现代医药杂志, 2015, 17(9):4-8. DOI: 10.3969/j.issn.1672-9463.2015.09.002. doi: 10.3969/j.issn.1672-9463.2015.09.002
[17]	JEONG S Y, KIM J E, SONG G Y, et al. Rgx365, a rare protopanaxatriol-type ginsenoside fraction from Black Ginseng, suppresses inflammatory gene iNOS via the iinhibition of p-STAT-1 and NF-B[J]. The American Journal of Chinese Medicine, 2020, 48(5):1091-1102. DOI: 10.1142/S0192415X20500536. doi: 10.1142/S0192415X20500536
[18]	宋金玥, 任锋, 张向颖, 等. 山奈酚干预对D-氨基半乳糖/脂多糖诱导小鼠急性肝衰竭的保护作用[J]. 中国中西医结合杂志, 2017, 37(5):569-574. DOI: 10.7661/j.cjim.20170315.042. doi: 10.7661/j.cjim.20170315.042
[19]	BAHADIR Ö, ÇITOĞLU G S, ÖZBEK H, et al. Hepatoprotective and TNF-α inhibitory activity of Zosima absinthifolia extracts and coumarins[J]. Fitoterapia, 2011, 82(3):454-9. DOI: 10.1016/j.fitote.2010.12.007. doi: 10.1016/j.fitote.2010.12.007
[20]	程海飞, 陈艳琳, 范绍辉, 等. MAPK信号通路在急性肺损伤进程中的研究进展[J]. 医学综述, 2020, 26(13):2523-2528. DOI: 10.3969/j.issn.1006-2084.2020.13.006. doi: 10.3969/j.issn.1006-2084.2020.13.006
[21]	TSAI M S, WANG Y H, LAI Y Y, et al. Kaempferol protects against propacetamol-induced acute liver injury through CYP2E1 inactivation, UGT1A1 activation, and attenuation of oxidative stress, inflammation and apoptosis in mice[J]. Toxicology Letters, 2018, 290:97-109. DOI: 10.1016/j.toxlet.2018.03.024. doi: 10.1016/j.toxlet.2018.03.024
[22]	AMALAKUHAN B, HABIB S A, MANGAT M, et al. Endothelial adhesion molecules and multiple organ failure in patients with severe Sepsis[J]. Cytokine, 2016, 88:267-273. DOI: 10.1016/j.cyto.2016.08.028. doi: 10.1016/j.cyto.2016.08.028
[23]	KIM I, MOON S O, KIM S H, et al. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells[J]. The Journal of Biological Chemistry, 2001, 276(10):7614-7620. DOI: 10.1074/jbc.M009705200. doi: 10.1074/jbc.M009705200
[24]	YANO K, LIAW P C, MULLINGTON J M, et al. Vascular endothelial growth factor is an important determinant of Sepsis morbidity and mortality[J]. The Journal of Experimental Medicine, 2006, 203(6):1447-1458. DOI: 10.1084/jem.20060375. doi: 10.1084/jem.20060375
[25]	HU W H, WANG H Y, XIA Y T, et al. Kaempferol, a major flavonoid in Ginkgo folium, potentiates angiogenic functions in cultured endothelial cells by binding to vascular endothelial growth factor[J]. Frontiers in Pharmacology, 2020, 11:526. DOI: 10.3389/fphar.2020.00526. doi: 10.3389/fphar.2020.00526
[26]	ZHANG J F, LUO Y F, WANG X L, et al. Global transcriptional regulation of STAT3 and MYC-mediated sepsis-induced ARDS[J]. Therapeutic Advances in Respiratory Disease, 2019, 13(3):175346661987984. DOI: 10.1177/1753466619879840. doi: 10.1177/1753466619879840
[27]	谢璨灿, 曾维忠, 吴双华, 等. 脓毒症患者外周血单个核细胞STAT3 mRNA表达及其对预后的预测价值[J]. 山东医药, 2020, 60(20):51-54. DOI: 10.3969/j.issn.1002-266X.2020.20.013. doi: 10.3969/j.issn.1002-266X.2020.20.013
[28]	BASU A, DAS A S, SHARMA M, et al. STAT3 and NF-κB are common targets for kaempferol-mediated attenuation of COX-2 expression in IL-6-induced macrophages and carrageenan-induced mouse paw edema[J]. Biochemistry and Biophysics Reports, 2017, 12:54-61. DOI: 10.1016/j.bbrep.2017.08.005. doi: 10.1016/j.bbrep.2017.08.005
[29]	卓荦, 史家欣, 李小民. PI3K/AKT/mTOR信号通路对脓毒症中细胞自噬的调控研究进展[J]. 重庆医学, 2019, 48(11):1927-1929. DOI: 10.3969/j.issn.1671-8348.2019.11.033. doi: 10.3969/j.issn.1671-8348.2019.11.033
[30]	阳凤, 尹德锋, 刘济滔, 等. P38MAPK信号通路在大鼠脓毒症致急性肺损伤中的作用及机制研究[J]. 四川医学, 2020, 41(4):361-365. DOI: 10.16252/j.cnki.issn1004-0501-2020.04.007. doi: 10.16252/j.cnki.issn1004-0501-2020.04.007
[31]	谢宇曦, 王建军, 部媛媛, 等. 脓毒症休克后肝组织RAS的表达变化及其与肝损害的关系[J]. 中国煤炭工业医学杂志, 2016, 19(11):1611-1614. DOI: 10.11723/mtgyyx1007-9564201611022. doi: 10.11723/mtgyyx1007-9564201611022
[32]	姚洁, 林名瑞, 陈怀宇, 等. 犀角地黄汤对脓毒症大鼠脾组织PLATELATE ACTIVATION通路相关基因表达的影响[J]. 蛇志, 2020, 32(4):424-428. DOI: 10.3969/j.issn.1001-5639.2020.04.008. doi: 10.3969/j.issn.1001-5639.2020.04.008
[33]	薛莲. 氢气调节脓毒症小鼠肺组织内HIF-1α水平[D]. 天津:天津医科大学, 2018.